Platelet Indices and Blood Groups in Type 2 Diabetes Vascular Complications

September 23, 2026 updated by: Nehal Sayed Mohammed Sayed, Assiut University

Association of Platelet Indices and Blood Groups With Vascular Complications in Patients With Type 2 Diabetes Mellitus

This cross-sectional study aims to evaluate the association of platelet indices and ABO blood groups with vascular complications in patients with type 2 diabetes mellitus.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

Vascular complications are a major cause of morbidity in type 2 diabetes mellitus. Platelet indices and ABO blood groups may be related to these complications.

This observational study will include adult patients with type 2 diabetes mellitus. Patients will be classified into those with and without vascular complications. Platelet indices (MPV, PDW) and ABO blood groups will be assessed.

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adult patients with type 2 diabetes mellitus attending the Internal Medicine Department and Diabetes Center at Assiut University Hospital.

Description

Inclusion Criteria:

  • Age 18 years or older
  • Confirmed diagnosis of type 2 diabetes mellitus according to ADA criteria
  • Written informed consent

Exclusion Criteria:

  • Type 1 diabetes mellitus
  • Gestational diabetes
  • Acute infection or sepsis
  • Hematological disorders affecting platelet count or function
  • Malignancy
  • Chronic liver disease
  • Autoimmune diseases
  • Current anticoagulant or antiplatelet therapy
  • Recent major surgery or trauma
  • Pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: CASE_CONTROL
  • Time Perspectives: CROSS_SECTIONAL

Cohorts and Interventions

Group / Cohort
T2DM with Vascular Complications

Patients with type 2 diabetes mellitus who have microvascular or macrovascular complications.
T2DM without Vascular Complications

Patients with type 2 diabetes mellitus who have no microvascular or macrovascular complications.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean platelet volume in patients with and without vascular complications
Time Frame: Baseline

Mean platelet volume (MPV) in femtoliters compared between type 2 diabetes patients with vascular complications and those without vascular complications.
Baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean platelet distribution width
Time Frame: Baseline

Mean platelet distribution width (PDW) compared between patients with and without vascular complications.
Baseline
Distribution of ABO blood groups according to vascular complications
Time Frame: Baseline

Frequency and percentage of ABO blood groups in patients with and without vascular complications.
Baseline
Mean platelet volume according to ABO blood group
Time Frame: Baseline

Mean platelet volume (MPV) among different ABO blood groups.
Baseline
Prevalence of microvascular complications
Time Frame: Baseline

Proportion of patients with microvascular complications (retinopathy, nephropathy, or neuropathy).
Baseline
Prevalence of macrovascular complications
Time Frame: Baseline

Proportion of patients with macrovascular complications (coronary artery disease, cerebrovascular disease, or peripheral arterial disease).
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Investigators

  • Study Chair: Lobna F El-toony, Internal Medicine Department, Assiut University Hospitals

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 26, 2026

Primary Completion (Estimated)

September 26, 2027

Study Completion (Estimated)

March 25, 2028

Study Registration Dates

First Submitted

September 23, 2026

First Submitted That Met QC Criteria

September 23, 2026

First Posted (Actual)

September 29, 2026

Study Record Updates

Last Update Posted (Actual)

September 29, 2026

Last Update Submitted That Met QC Criteria

September 23, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Platelet-T2DM-Assiut-2026

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe